1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Desh Rakshak Aushdhalaya Ltd.

Desh Rakshak Aushdhalaya Ltd.

BBSE:DESHRAK
26.90
INR
0.00
(0.00%)
0.97EPS
35.41P/E
196.73MMarket Cap
Desh Rakshak Aushdhalaya Ltd.
BSE:DESHRAK
(Bombay Stock Exchange)

Recent

price

26.90

P/E

ratio

35.41

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
8.48
8.61
8.65
9
10.04
11.11
11.45
11.47
12.5
11.46
14.87
13.95
2.06
13.53
14.13
12.47
11.64
Revenue per Share
-0.14
- -
-0.01
0.15
0.05
0.66
0.63
0.64
0.76
0.69
0.95
1.08
0.14
0.96
1.07
0.99
0.97
Basic EPS, GAAP
-2.42
-0.44
-0.79
- -
- -
0.43
-0.23
-0.59
-1.24
-1.49
-1.22
-3.39
-0.12
3.3
-1.96
-4.92
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
15.87
15.87
15.15
- -
15.36
16.04
16.67
17.31
18.27
18.89
19.83
20.92
20.58
21.36
22.43
23.32
- -
Book Value per Share
15.87
15.87
15.15
- -
15.36
16.04
16.67
17.31
18.27
18.89
19.83
20.92
20.58
21.36
22.43
23.32
- -
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
4
4
4
30
4
4
6
6
Basic Weighted Avg Shares
38
38
38
40
45
49
51
51
55
51
66
62
62
60
63
71
66
Sales/Revenue/Turnover
3.36
5.62
2.12
4.9
4.42
9.91
8.7
9.23
9.77
11.13
11.04
13.16
15.49
14.6
13.44
17.37
14.15
Operating Margin (%)
2
1
2
4
5
2
2
2
2
3
3
4
4
4
4
4
4
Depreciation Expense
-1
- -
- -
1
- -
3
3
3
3
3
4
5
4
4
5
6
6
Net Income, GAAP
738.56
99.21
110
43.39
70.07
23.83
17.48
19.06
19.24
19.24
23.17
15.6
15.6
15.6
15.6
16.74
17
Effective Tax Rate (%)
-1.7
0.01
-0.09
1.7
0.54
5.91
5.54
5.56
6.05
5.99
6.37
7.78
6.56
7.12
7.6
7.91
8.32
Profit Margin (%)
23
29
27
- -
26
22
20
23
25
25
27
30
26
19
30
65
- -
Working Capital
- -
4
9
- -
8
15
10
12
14
22
30
43
42
28
31
32
- -
LT Debt
70
70
67
- -
68
71
74
77
81
84
88
93
91
95
100
133
- -
Total Equity
-0.86
- -
-0.05
- -
- -
3.49
3.19
4.27
4.7
4.51
4.98
5.35
3
3.32
5.57
5.46
- -
Return on Invested Capital (%)
-0.86
- -
-0.05
- -
- -
4.39
3.28
4.29
4.75
4.23
4.71
5.19
5.56
5.7
5.78
5.38
- -
Return on Capital (%)
-0.9
- -
-0.05
- -
- -
4.18
3.88
3.75
4.25
3.7
4.89
5.32
4.4
4.59
4.91
4.84
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
32
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
187
154
197

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
109
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
92
- -
Inventories
- -
3
- -
Total Current Liabilities
- -
44
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.79%
9.23%
33.49%
Free Cash Flow
-23.44%
-70.09%
222.44%
Net Income, GAAP
7.8%
6.73%
17.95%
Sales/Revenue/Turnover
4.21%
1.71%
13.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
11
12
19
44
63
2026
13
10
14
35
71
2027
8
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.21
0.33
0.27
0.8
1.07
2026
0.22
0.15
0.16
0.52
0.99
2027
0.14
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Desh Rakshak Aushdhalaya Ltd manufactures and sells pure ayurvedic and herbal products in India, operating as the flagship company of the Bhagwant Group with approximately 450 proprietary and classical medicines produced in compliance with Indian government standards. The company offers a wide range of ayurvedic medicines in tablet, capsule, pill, powder, syrup, and liquid forms; ayurvedic composite drug kits, dye kits, and CHW kits; specific products including Amalki Churna, Ashwagandha Tablet, Triphala Churna, Lavana Bhaskar Churna, Sat Shilajeet, Shunthi Churna, Hingwadi Churna, Gashar Vati, Buddhivardhak Yog, Balamrit, Lodhra Churna, Narayan Churna, Gangadhar Churna, Mustaka Churna, Shatavari Churna Tablet, Lavangadi Churna, Shringyadi Churna, Shatavaryadi Churna, Dant Mohini Manjan, Gokshur Churna, Bhringraj Churna, Mulethi Churna, Dashmool Kwath, Punarnavastak Kwath, and Giloy Satva; as well as ethical healthcare products derived from ancient ayurvedic formulations. Founded in 1901 and headquartered in Haridwar, India, it converted to a public limited company in 1994 and lists on the Bombay Stock Exchange under the ticker DESHRAK.BO, with exports to international markets and supplies to government departments. In November 2025, the company approved a fundraising initiative via warrants convertible into equity shares, marking a significant capital-raising effort amid recent financial performance showing net profit growth to Rs 0.36 crore in the March 2025 quarter.